Zasocitinib
Appearance
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C23H24N8O3 |
Molar mass | 460.498 g·mol−1 |
3D model (JSmol) | |
| |
|
Zasocitinib (TAK-279, NDI-034858) is a drug which is an orally active, highly selective tyrosine kinase 2 (TYK2) inhibitor. It has been researched for various inflammatory conditions including psoriatic arthritis and Crohn's disease.[1][2][3] It is significantly more selective than earlier compounds over side targets such as JAK1, which is hoped to give it an improved side effect profile.[4]
See also
[edit]References
[edit]- ^ Leit S, Greenwood J, Carriero S, Mondal S, Abel R, Ashwell M, et al. (August 2023). "Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279". Journal of Medicinal Chemistry. 66 (15): 10473–10496. doi:10.1021/acs.jmedchem.3c00600. PMID 37427891.
- ^ Kivitz AJ (14 November 2023). "The investigational tyrosine kinase inhibitor TAK-279 is effective and well tolerated in patients with active psoriatic arthritis in phase 2b study". Cleveland Clinic Journal of Medicine.
- ^ Kivitz A, Muensterman ET, Kavanaugh A, Van der Heijde D, Klimiuk PA, Valenzuela G, et al. (24 October 2023). "Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis". American College of Rheumatology.
- ^ "The Discovery Process of TAK-279 and the Deep Logic Behind its Acquisition by Takeda". synapse.patsnap.com. 10 August 2023.